A Phase II, randomised, double-blind, placebo-controlled study of the safety, tolerability and efficacy of topical AKP-11 administration to participants with plaque psoriasis.

Trial Profile

A Phase II, randomised, double-blind, placebo-controlled study of the safety, tolerability and efficacy of topical AKP-11 administration to participants with plaque psoriasis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs AKP 11 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Akaal Pharma
  • Most Recent Events

    • 14 Dec 2015 According to an Akaal Pharma media release, dosing in this trial will commence in January 2016.
    • 11 Dec 2015 Status changed from not yet recruiting to recruiting, as per Akaal Pharma media release.
    • 16 Jun 2015 According to an Akaal Pharma media release, the company received approval to initiate this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top